Research ExplorerPublicationsPCSK9 Inhibitor Wars: How Does Inclisiran Fit in with Curren...

PCSK9 Inhibitor Wars: How Does Inclisiran Fit in with Current Monoclonal Antibody Inhibitor Therapy? Considerations for Patient Selection

Standard

PCSK9 Inhibitor Wars: How Does Inclisiran Fit in with Current Monoclonal Antibody Inhibitor Therapy? Considerations for Patient Selection. / Arnold, Natalie; Koenig, Wolfgang.

In: CURR CARDIOL REP, Vol. 24, No. 11, 11.2022, p. 1657-1667.

Research output: SCORING: Contribution to journal › SCORING: Review article › Research

Harvard

Arnold, N & Koenig, W 2022, 'PCSK9 Inhibitor Wars: How Does Inclisiran Fit in with Current Monoclonal Antibody Inhibitor Therapy? Considerations for Patient Selection', CURR CARDIOL REP, vol. 24, no. 11, pp. 1657-1667. https://doi.org/10.1007/s11886-022-01782-6

APA

Arnold, N., & Koenig, W. (2022). PCSK9 Inhibitor Wars: How Does Inclisiran Fit in with Current Monoclonal Antibody Inhibitor Therapy? Considerations for Patient Selection. CURR CARDIOL REP, 24(11), 1657-1667. https://doi.org/10.1007/s11886-022-01782-6

Vancouver

Arnold N, Koenig W. PCSK9 Inhibitor Wars: How Does Inclisiran Fit in with Current Monoclonal Antibody Inhibitor Therapy? Considerations for Patient Selection. CURR CARDIOL REP. 2022 Nov;24(11):1657-1667. https://doi.org/10.1007/s11886-022-01782-6

Bibtex

@article{a7665181edae489aabedb489bb7c9e73,
title = "PCSK9 Inhibitor Wars: How Does Inclisiran Fit in with Current Monoclonal Antibody Inhibitor Therapy? Considerations for Patient Selection",
abstract = "PURPOSE OF REVIEW: Treatment of dyslipidemia represents one of the most crucial strategies to reduce risk of atherosclerotic cardiovascular (CV) disease (ASCVD). In this review, we critically summarize our knowledge on emerging cholesterol-lowering therapy, targeting PCSK9, paying particular attention on treatment allocation of two drug groups, currently available for clinical use, namely, anti-PCSK9 monoclonal antibodies (mAbs) and inclisiran, a first-in-class small interfering RNA against PCSK9.RECENT FINDINGS: Although both drug classes show a pronounced, but fairly similar reduction in LDL-cholesterol, their long-term safety is still unknown. Compared to mAbs, inclisiran has a more favorable dosing regimen with biannual application that might improve therapeutic adherence significantly. However, a CV outcome trial (CVOT) for inclisiran is still missing. If inclisiran will be safe and effective in ongoing/future CVOTs, it has a huge potential to overcome medication non-compliance, thereby providing a powerful therapeutic option to decrease the burden of ASCVD.",
keywords = "Humans, Patient Selection, Antibodies, Monoclonal/therapeutic use, RNA, Small Interfering/therapeutic use, Cholesterol, Proprotein Convertase 9",
author = "Natalie Arnold and Wolfgang Koenig",
note = "{\textcopyright} 2022. The Author(s).",
year = "2022",
month = nov,
doi = "10.1007/s11886-022-01782-6",
language = "English",
volume = "24",
pages = "1657--1667",
journal = "CURR CARDIOL REP",
issn = "1523-3782",
publisher = "Current Medicine Group",
number = "11",

}

RIS

TY - JOUR

T1 - PCSK9 Inhibitor Wars: How Does Inclisiran Fit in with Current Monoclonal Antibody Inhibitor Therapy? Considerations for Patient Selection

AU - Arnold, Natalie

AU - Koenig, Wolfgang

N1 - © 2022. The Author(s).

PY - 2022/11

Y1 - 2022/11

N2 - PURPOSE OF REVIEW: Treatment of dyslipidemia represents one of the most crucial strategies to reduce risk of atherosclerotic cardiovascular (CV) disease (ASCVD). In this review, we critically summarize our knowledge on emerging cholesterol-lowering therapy, targeting PCSK9, paying particular attention on treatment allocation of two drug groups, currently available for clinical use, namely, anti-PCSK9 monoclonal antibodies (mAbs) and inclisiran, a first-in-class small interfering RNA against PCSK9.RECENT FINDINGS: Although both drug classes show a pronounced, but fairly similar reduction in LDL-cholesterol, their long-term safety is still unknown. Compared to mAbs, inclisiran has a more favorable dosing regimen with biannual application that might improve therapeutic adherence significantly. However, a CV outcome trial (CVOT) for inclisiran is still missing. If inclisiran will be safe and effective in ongoing/future CVOTs, it has a huge potential to overcome medication non-compliance, thereby providing a powerful therapeutic option to decrease the burden of ASCVD.

AB - PURPOSE OF REVIEW: Treatment of dyslipidemia represents one of the most crucial strategies to reduce risk of atherosclerotic cardiovascular (CV) disease (ASCVD). In this review, we critically summarize our knowledge on emerging cholesterol-lowering therapy, targeting PCSK9, paying particular attention on treatment allocation of two drug groups, currently available for clinical use, namely, anti-PCSK9 monoclonal antibodies (mAbs) and inclisiran, a first-in-class small interfering RNA against PCSK9.RECENT FINDINGS: Although both drug classes show a pronounced, but fairly similar reduction in LDL-cholesterol, their long-term safety is still unknown. Compared to mAbs, inclisiran has a more favorable dosing regimen with biannual application that might improve therapeutic adherence significantly. However, a CV outcome trial (CVOT) for inclisiran is still missing. If inclisiran will be safe and effective in ongoing/future CVOTs, it has a huge potential to overcome medication non-compliance, thereby providing a powerful therapeutic option to decrease the burden of ASCVD.

KW - Humans

KW - Patient Selection

KW - Antibodies, Monoclonal/therapeutic use

KW - RNA, Small Interfering/therapeutic use

KW - Cholesterol

KW - Proprotein Convertase 9

U2 - 10.1007/s11886-022-01782-6

DO - 10.1007/s11886-022-01782-6

M3 - SCORING: Review article

C2 - 36087240

VL - 24

SP - 1657

EP - 1667

JO - CURR CARDIOL REP

JF - CURR CARDIOL REP

SN - 1523-3782

IS - 11

ER -